NEW YORK (TheStreet) -- CHANGE IN RATINGS

Boston Scientific ( BSX) downgraded at Goldman from Neutral to Sell. Stock also added to the Conviction list, as the company could lose market share.

Clorox ( CLX) upgraded at Barclays to Overweight from Equal Weight as the company is experiencing top line momentum. Price target jumped to $71 from $67. 2010 and 2011 EPS estimates set at $4.23 and $4.73, respectively.

Coventry Health ( CVH) upgraded at Goldman from Sell to Neutral. Valuation call.

Onyx Pharmaceuticals ( ONXX) upgraded at Goldman from Neutral to Buy. $37 price target. Company has an attractive pipeline, and good be an attractive acquisition target.

Parexel ( PRXL) upgraded at Goldman to Buy. Company can deliver above-average earnings growth.

Psychiatric Solutions ( PSYS) downgraded at Wells from Outperform to Market Perform. Stock is already pricing in a potential buyout.

Starbucks ( SBUX) upgraded at UBS from Neutral to Buy. $29 price target. Estimates also raised, given the company's strong sales and earnings momentum.

Universal American ( UAM) downgraded at Goldman from Neutral to Sell. Stock was also added to the Conviction list, based on valuation.

Pharmasset ( VRUS) initiated at Citi with a Buy rating and $34 price target. RG7128 should become a major drug in the hepatitis C market.

Western Union ( WU) downgraded at William Blair from Outperform to Market Perform. Valuation call, as the stock lacks catalysts.

Wyndham Worldwide ( WYN) downgraded at Goldman from Buy to Neutral. Valuation call, based on a $26 price target.

STOCK COMMENTS / EPS CHANGES

Alexion Pharma ( ALXN) added to Conviction Buy List at Goldman. Stock is not yet pricing in positive fundamental momentum.

Boston Scientific ( BSX) numbers cut at UBS. Shares of BSX now seen reaching $8. Estimates also lowered, as the company could lose six months of ICD sales. Buy rating.

Peabody Energy ( BTU) price target boosted at Barclays to $62 from $58. 2010 and 2011 EPS estimates maintained at $2.55 and $4.40. Overweight rating.

EnerNOC ( ENOC) estimates changed at Credit Suisse ENOC 2010 EPS estimate raised to 38 cents, 2011 lowered to 36 cents. Maintain Outperform rating and $40 price target.

Ford ( F) estimates, target increased at UBS. Shares of F now seen reaching $15. Estimates also upped, as the company is likely to gain market share from other U.S. makers. Buy rating.

Kimberly-Clark ( KMB) added to Conviction Sell List at Goldman. Estimates also lowered, because of rising pulp prices. $57 price target.

Kansas City Southern ( KSU) numbers increased at Goldman. KSU estimates were boosted through 2012. Company is seeing higher cross-border traffic with Mexico. Neutral rating and new $40 price target.

Limited Brands ( LTD) estimates higher at Credit Suisse. LTD 2011 and 2012 EPS estimates boosted to $1.64 and $1.95, respectively. The company announced a special $1/share dividend and new $200 million buyback plan. Maintain Neutral rating and $20 price target.

Limited Brands ( LTD) numbers boosted at Goldman. Shares of LTD now seen reaching $24. Estimates also increased, given the company's buyback program. Neutral rating.

Microchip ( MCHP) estimates raised at UBS through 2011. Company is seeing solid bookings and shipments. Neutral rating and $28 price target.

Massey Energy ( MEE) price target raised at Barclays to $56 from $56. Equal Weight rating. 2010 and 2011 EPS estimates set at $1.25 and $2.15, respectively.

Priceline.com ( PCLN) estimates raised at Goldman. PCLN estimates were increased through 2012. Numbers updated for recent convertible offering. Buy rating.

Research in Motion ( RIMM) estimate tweaked at Barclays. RIMM 2011 EPS estimates lifted 5 cents to $5.08, 2010 held at $4.40. Maintain Overweight rating and $85 price target.

Swift Energy ( SFY) numbers increased at UBS through 2011. Company can deliver strong production growth and reserve replacement. Buy rating and new $38 price target.

St. Jude ( STJ) removed from Conviction Sell List at Goldman Sachs. Company can gain market share, though pricing pressures remain.

Teva Pharma ( TEVA) cut from Conviction Buy List at Goldman Sachs. Valuation call.

UnitedHealth ( UNH) cut from Conviction Buy List at Goldman Sachs. Company has continued exposure to Medicare Advantage.

Valley National ( VLY) estimates raised at UBS. VLY estimates were boosted through 2011. FDIC acquisitions should add to earnings. Sell rating and $11 price target.

This article was written by a staff member of TheStreet.com.

More from Stocks

Spotlight On Space Exploration as Jeff Bezos' Blue Origin Sets Ticket Sale Date

Spotlight On Space Exploration as Jeff Bezos' Blue Origin Sets Ticket Sale Date

This Will Be the Ultimate Buy (or Sell) Signal for Stocks

This Will Be the Ultimate Buy (or Sell) Signal for Stocks

3 Fierce Chinese Tech Stocks to Gamble on Right Now

3 Fierce Chinese Tech Stocks to Gamble on Right Now

Stocks Slammed on Latest Trump Tariff Fears

Stocks Slammed on Latest Trump Tariff Fears

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War